Daily Cardiology Research Analysis
Analyzed 57 papers and selected 3 impactful papers.
Summary
Analyzed 57 papers and selected 3 impactful articles.
Selected Articles
1. MARCH2 prevents doxorubicin-induced cardiomyopathy by stabilizing NR1H2 and promoting clearance of apoptotic cardiomyocytes.
This mechanistic study identifies the MARCH2–NR1H2 (LXRβ) axis as central to cardiac macrophage efferocytosis in doxorubicin-induced cardiomyopathy. MARCH2 expression is reduced in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients; genetic ablation implicates loss of MARCH2 in impaired apoptotic cell clearance.
Impact: Revealing a druggable macrophage pathway that preserves efferocytosis directly addresses a key mechanism of chemotherapy cardiotoxicity and opens avenues for cardioprotective strategies in oncology.
Clinical Implications: Targeting the MARCH2–NR1H2 axis could become a cardioprotective adjunct during anthracycline therapy, potentially reducing heart failure risk without compromising oncologic efficacy.
Key Findings
- Identified the MARCH2–NR1H2 (LXRβ) axis as a central regulator of cardiac macrophage efferocytosis in DiCM.
- Observed significantly reduced MARCH2 expression in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients.
- Genetic ablation of MARCH2 implicated loss of MARCH2 in impaired apoptotic cardiomyocyte clearance.
Methodological Strengths
- Mechanistic, multi-system approach with mouse models and human patient samples.
- Direct focus on macrophage efferocytosis, a causal pathway in anthracycline cardiotoxicity.
Limitations
- Preclinical mechanistic data; clinical efficacy of targeting MARCH2–NR1H2 remains untested.
- Abstract does not provide detailed outcomes or translational intervention data.
Future Directions: Validate MARCH2–NR1H2 modulation in large-animal models; develop small-molecule or gene-based strategies to augment efferocytosis; assess cardioprotection without impairing anti-tumor efficacy.
Doxorubicin-induced cardiomyopathy (DiCM) involves impaired clearance of apoptotic cardiomyocytes (efferocytosis) by cardiac macrophages. This study reveals a central role for the MARCH2-NR1H2 axis in this process. We find that MARCH2 expression is significantly reduced in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients. Genetic ablation of MARCH2, either globally (MARCH2
2. Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening.
In older adults undergoing carpal tunnel surgery, tenosynovial amyloid was detected in 56%, and among biopsy-positive patients, 17.3% had ATTR-CM—most at early stage (89% NAC stage I). Age- and biopsy-guided screening thus identifies ATTR-CM earlier than routine clinical pathways.
Impact: This pragmatic screening strategy captures ATTR-CM at an earlier, potentially more treatable stage and can be embedded in routine orthopedic workflows.
Clinical Implications: Consider tenosynovial biopsy during CTS surgery for older patients, with downstream cardiac workup when amyloid is present, to accelerate ATTR-CM diagnosis and treatment initiation.
Key Findings
- Tenosynovial amyloid deposition was found in 61/109 (56.0%) CTS patients screened.
- Among amyloid-positive patients who completed cardiac evaluation, 9/52 (17.3%) had ATTR-CM.
- Screening-detected ATTR-CM cases had milder disease: 89% were NAC stage I versus 55% in clinically diagnosed controls.
Methodological Strengths
- Prospective, multicenter design with standardized biopsy and cardiac workup.
- Inclusion of a contemporary clinically diagnosed control cohort for severity comparison.
Limitations
- Modest sample size with limited number of confirmed ATTR-CM cases.
- Potential selection bias to surgical CTS population; generalizability beyond older CTS patients is uncertain.
Future Directions: Assess cost-effectiveness, refine age/sex thresholds, and evaluate routine biopsy pathways across diverse health systems; determine impact on time-to-diagnosis and outcomes with disease-modifying therapy.
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is frequently preceded by carpal tunnel syndrome (CTS). The value of age- and biopsy-guided screening during CTS surgery for early detection of ATTR-CM remains uncertain. OBJECTIVES: We aimed to determine the proportion of amyloid deposition in tenosynovial biopsies, the proportion of ATTR-CM among biopsy-positive patients, and to compare disease severity between screening-detected and clinically diagnosed ATTR-CM patients. METHODS: This prospective, multicenter cohort study enrolled men ≥65 and women ≥75 years undergoing surgery for idiopathic CTS and analyzed tenosynovial biopsies for amyloid deposition. Patients with amyloid-positive biopsies underwent cardiac workup, including echocardiography, bone scintigraphy, biomarker testing, and genetic testing to confirm ATTR-CM. A control cohort of contemporary clinically diagnosed wildtype ATTR-CM patients was included for comparison. RESULTS: In total, 109 CTS patients were included (median age 79 years [IQR: 75-82]). Tenosynovial amyloid deposition was detected in 61/109 patients (56.0%; 95% CI: 46.1-65.5), of whom 52/61 patients completed cardiac evaluation. ATTR-CM was diagnosed in 9/52 patients (17.3%; 95% CI: 8.2-30.3; median age 83 years [IQR: 80-84]; male-to-female ratio 3.5:1; n = 7/2). Patients identified through screening had milder disease, 8/9 (89%) were in the National Amyloidosis Centre stage I compared to 26/47 (55%) among clinically diagnosed patients. CONCLUSIONS: Systematic age- and biopsy-guided screening during CTS surgery identified a high proportion of carpal amyloid deposition. Among amyloid-positive CTS patients, 1 in 6 was diagnosed with early-stage ATTR-CM. This approach demonstrated a higher yield in identifying ATTR-CM with mild disease burden and may serve as a tool for earlier diagnosis.
3. Inflammation and day-to-day occurrence of atrial fibrillation.
Linking >1.2 million monitored person-days to >7,000 CRP tests, CRP was significantly higher on AF days versus non-AF days, with each CRP doubling raising AF odds by 36%. A clear dose-response and within-person SCCS signal support inflammation as an acute AF trigger.
Impact: Establishes temporal, dose-dependent coupling of systemic inflammation with AF episodes, motivating trials of anti-inflammatory or infection-targeted strategies to prevent AF events.
Clinical Implications: CRP may serve as a dynamic risk signal to guide monitoring intensity, trigger evaluation for inflammatory sources, or personalize upstream anti-inflammatory strategies in AF-prone patients.
Key Findings
- On AF days, CRP was higher than on non-AF days (8.37 vs 4.02 mg/L, geometric means).
- Each doubling of CRP was associated with 36% higher odds of AF (adjusted OR 1.36 [1.26–1.47]).
- CRP >10–50 mg/L and >50 mg/L increased AF odds (aOR 3.50 and 5.75 versus ≤3 mg/L); SCCS showed CRP >10 mg/L raised AF incidence (IRR 2.41).
Methodological Strengths
- Day-level linkage of continuous ILR data to temporally proximate CRP samples.
- Use of mixed models and self-controlled case series to address between- and within-person confounding.
Limitations
- Post-hoc exploratory analysis with potential residual confounding and selection effects.
- CRP sampling was intermittent and may miss brief inflammatory fluctuations or causal antecedents.
Future Directions: Test inflammation-targeted interventions (e.g., anti-inflammatory agents or infection control) triggered by biomarker thresholds; evaluate high-frequency biomarker sampling and multi-omics to refine AF risk prediction.
BACKGROUND AND AIMS: Inflammation is central in atrial fibrillation (AF) pathophysiology, but the temporal association between inflammatory activity and AF remains uncertain. This study investigated the day-to-day relationship between plasma C-reactive protein (CRP) levels and AF occurrence in continuously monitored individuals. METHODS: Post-hoc analysis of the LOOP study randomizing participants with stroke risk factors to implantable loop recorder (ILR) screening (n=1501) or usual care. ILR raw data were linked to blood samples collected within one day. The outcome was AF episodes lasting ≥60 minutes. Associations were examined using generalized and linear mixed models and as a self-controlled case series (SCCS). RESULTS: ILR and CRP data were available for 1065 participants combining >1.2 million days of heart rhythm monitoring (including ∼40,000 days with AF) with >7,000 CRP measurements. CRP was higher during days with AF (geometric mean 8.37 [7.11-9.86] mg/L) versus non-AF days (4.02 [3.71-4.35] mg/L). Each doubling of CRP was associated with 36% higher odds of AF (adjusted odds ratio [aOR] 1.36 [1.26-1.47]). Compared with CRP ≤3 mg/L, the odds of AF increased for CRP >10-50 mg/L and >50 mg/L (aOR 3.50 [2.18-5.60] and 5.75 [3.48-9.50], respectively). In SCCS analyses, CRP >10 mg/L was associated with higher incidence of AF compared to lower levels (incidence rate ratio 2.41 [1.53-3.80]). CONCLUSIONS: This exploratory study found a temporal and dose-response relationship between CRP levels and AF occurrence, supporting inflammation as an acute trigger and underscoring the need to evaluate inflammatory markers as potential targets in AF management.